Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-05843-x
Abstract: One popular and well-established marker for the immune checkpoint blockade (ICB) response is tumor mutation burden (TMB). Persistent TMB (pTMB), a subset of TMB, provides a better indicator to predict patient ICB therapy outcomes, as…
read more here.
Keywords:
mutation burden;
ptmb;
tumor mutation;
Sign Up to like & get
recommendations!
0
Published in 2018 at "Medical hypotheses"
DOI: 10.1016/j.mehy.2018.05.005
Abstract: Immune checkpoint inhibitors have profoundly altered the therapeutic landscape of several malignancies. The establishment of predictive biomarkers for checkpoint blockades is of the considerable importance in the identification of populations likely to experience a good…
read more here.
Keywords:
clinical benefit;
immunotherapy;
tumor mutation;
burden ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Bioscience Reports"
DOI: 10.1042/bsr20203336
Abstract: Abstract Tumor mutation burden (TMB) was a promising marker for immunotherapy. We aimed to investigate the prognostic role of TMB and its relationship with immune cells infiltration in gastric cancer (GC). We analyzed the mutation…
read more here.
Keywords:
infiltration;
mutation burden;
gastric cancer;
tumor mutation ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Briefings in Bioinformatics"
DOI: 10.1093/bib/bbaf455
Abstract: Abstract Accurate tumor mutation burden (TMB) quantification is critical for immunotherapy stratification, yet remains challenging due to variability across sequencing platforms, tumor heterogeneity, and variant calling pipelines. Here, we introduce TMBquant, an explainable AI-powered caller…
read more here.
Keywords:
mutation burden;
tmbquant explainable;
powered caller;
tumor ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13070
Abstract: SMARCA4 is a subunit of the switch/sucrose non‐fermentable (SWI/SNF) chromatin‐remodeling complex. An effective treatment for SMARCA4‐deficient non‐small cell lung carcinoma (NSCLC) has not yet been established. Correlations between a response to immune checkpoint inhibitors and…
read more here.
Keywords:
tumor mutation;
treatment;
smarca4 deficient;
high tumor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13163
Abstract: Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non‐invasively predict the…
read more here.
Keywords:
radiomics signature;
tumor mutation;
driver mutations;
stage lung ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Computational and Mathematical Methods in Medicine"
DOI: 10.1155/2021/1435827
Abstract: Thyroid carcinoma is a type of prevalent cancer. Its prognostic evaluation depends on clinicopathological features. However, such conventional methods are deficient. Based on mRNA, single nucleotide variants (SNV), and clinical information of thyroid carcinoma from…
read more here.
Keywords:
prognostic signature;
thyroid carcinoma;
tumor mutation;
signature ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "BioMed Research International"
DOI: 10.1155/2022/2698190
Abstract: Immunotherapy has been widely used in the treatment of lung cancer, and one of the most effective biomarkers for the prognosis of immunotherapy currently is tumor mutation burden (TMB). Although whole-exome sequencing (WES) could be…
read more here.
Keywords:
lung cancer;
tumor mutation;
mutation burden;
model ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0903
Abstract: Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research. We read with…
read more here.
Keywords:
burden response;
tumor mutation;
mutation burden;
pembrolizumab letter ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1073
Abstract: We have carefully reviewed the letter from Li and colleagues and believe that there were misunderstandings of the results and interpretation of the findings, which we would like to take the opportunity to clarify. We…
read more here.
Keywords:
burden response;
response;
tumor mutation;
mutation burden ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-2771
Abstract: Background: The Cancer Genome Atlas (TCGA) has identified 16% of colorectal cancers (CRC) to have defects in mechanisms that repair spontaneous DNA damage, and consequently have high tumor mutation burden (TMB). Although, there is accumulating…
read more here.
Keywords:
chemotherapy;
tmb;
tumor mutation;
cancer ... See more keywords